

Press Room

* TOP STORY

- PRESS RELEASE ARCHIVES
- FACT SHEETS
- SCIENCE WRITER'S GUIDES
- MEDIA DOWNLOADS LIBRARY
- Section MEDIA CONTACTS
- S ABOUT TAKEDA
- COMPLETE PRESCRIBING INFORMATION





Press Release Archives

Takeda Submits New Drug Application for Extended-Release Type 2 Diabetes Medication, ACTOS*plus* met(tm) (pioglitazone HCl and metformin HCl)

<u>New Data Shows Takeda's ACTOS® (pioglitazone HCI) Reduced Heart Attacks By 28 Percent</u> in People with Type 2 Diabetes

PROactive Study Shows Takeda's ACTOS® (pioglitazone HCI) Reduced Heart Attacks, Strokes and Deaths in Patients with Type 2 Diabetes

Use of website is governed by the Terms of Use and Privacy Statement.